Transdermal Nicotine Therapy and Primary Care: Importance of Counseling, Demographic, and Participant Selection Factors on 1-Year Quit Rates

Archives of Family Medicine

Volumn 7, Issue 5, 1998, Pages 425-430

  Daughton, David ^a,e   Susman, Jeffrey ^a   Sitorius, Michael ^a   Belenky, Sergei ^a   Millatmal, Tajuddin ^a   Nowak, Robert ^c,d   Patil, Kashinath ^b   Rennard, Stephen I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c SANOFI   (France)

^d Quantum Clinical Research   (United States)

^e NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NICOTINIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING CESSATION; STATISTICS; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, CUTANEOUS; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBRASKA; NICOTINE; NICOTINIC AGONISTS; PATIENT SELECTION; PRIMARY HEALTH CARE; RISK FACTORS; SMOKING CESSATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032161750     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.7.5.425     Document Type: Article

References (14)

1. Rose J, Levin ED, Behm FM, Adivi C, Schur C. Transdermal nicotine facilitates smoking cessation. Clin Pharmacol Ther. 1990;47:323-330.
2. Daughton DM, Heatley SA, Prendergast JJ, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. Arch Intern Med. 1991;151:749-752.
3. The Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. JAMA. 1991;266:3133-3138.
4. Tonneson P, Norregaard J, Simonsen K, Sawe U. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med. 1991;325: 311-315.
5. Sachs DPL, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting without intensive group counseling. Arch Intern Med. 1993;153:1881-1890.
6. Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. JAMA. 1994;271: 595-600.
7. ICRF General Practice Research Group. Randomized trial of nicotine patches in general practice: results at one year. BMJ. 1994;308:1476-1477.
8. Stapleton JA, Russell MA, Feyerabend C, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction. 1995;90:31-42.
9. National Center for Health Statistics. Health, United States 1987. Washington, DC: US Government Printing Office; 1988. DHHS publication (PHS) 88-1232.
10. Schwartz JL. Review and Evaluation of Smoking Cessation Methods: The United States and Canada, 1978-1985. Rockville, Md: US Dept of Health and Human Services; 1987. NIH publication 87-2940.
11. Emmons KM, Goldstein MG. Smokers who are hospitalized: a window of opportunity for cessation interventions. Prev Med. 1992;21:262-269.
12. Kviz FJ, Clark MA, Crittenden KS, Warnecke RB, Freels S. Age and smoking cessation behaviors. Prev Med. 1995;24:297-307.
13. Garvey AJ, Bosse R, Glynn RJ, Rosner B. Smoking cessation in a prospective study of healthy adults: effects of age, time period and amount smoked. Am J Public Health. 1983;73:446-450.
14. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation: who will quit with and without the nicotine patch. JAMA. 1994; 271:589-594.